BioDelivery Sciences International, Inc. (NASDAQ:BDSI) and Endo Pharmaceuticals announced Monday morning that its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients successfully met its primary efficacy endpoint. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) weekly performance is 8.74%. On last trading day company shares ended up $13.06. Analysts mean target price for the company is $17.81. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) distance from 50-day simple moving average is 28.71%.
The FDA approved Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Beleodaq for the treatment of patients suffering from relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). Beleodaq was approved well ahead of the target date of Aug 9 under the FDA’s accelerated approval program. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares advanced 3.03% in last trading session and ended the day on $8.63. SPPI Gross Margin is 82.10% and its return on assets is -19.10%. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) quarterly performance is 19.86%.
On June 10,2014 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program’s goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014.AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares moved up 3.05% in last trading session and was closed at $1.27, while trading in range of $1.23-$1.30. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) year to date performance is -7.97%.
AcelRx Pharma (NASDAQ: ACRX) and Grunenthal Group announced that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISOTM is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device. AcelRx and Grunenthal entered into license and supply agreements for ZALVISOTM in the EU, Australia and certain other countries in December 2013. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) ended the last trading day at $11.16. Company weekly volatility is calculated as 4.93% and price to cash ratio as 5.21. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) showed a positive weekly performance of 8.88%.
NeoGenomics, Inc. (NASDAQ: NEO) announced that it plans to release its second quarter 2014 financial results on Thursday July 17, 2014.NeoGenomics, Inc. (NASDAQ:NEO) net profit margin is 3.20% and weekly performance is 23.03%. On last trading day company shares ended up $4.06. Analysts mean target price for the company is $5.75. NeoGenomics, Inc. (NASDAQ:NEO) distance from 50-day simple moving average is 21.76%.